Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects With Solid Tumors

NCT02482168 is registered in ClinicalTrials.gov with Apexigen America, Inc. as lead sponsor.

NCT NCT02482168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02482168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects With Solid Tumors
Lead sponsor
Apexigen America, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2015
Completion date
June 19, 2018
Enrollment
43 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, head and neck cancer, melanoma, msi-h, nsclc, urothelial carcinoma